Terry Novak

Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate speed-to-market by prioritizing technical alignment, robust project management, and early-stage collaboration with the right CDMO partner.

Reducing Risk in Small Molecule Development: Choosing the Right CDMO Partner

Terry Novak from Benuvia reviews the key strategies for reducing risk in small molecule development by prioritizing technical alignment and robust project management when selecting a contract development and manufacturing organization (CDMO). He explains how early collaboration is critical to accelerating timelines and ensuring a seamless transition from development to large-scale GMP manufacturing. He also covers emerging industry trends, including the strategic move toward reshoring and the increased demand for specialized expertise in niche markets.

Terry Novak

Articles